{"entity":{"id":"nct05629234","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)","aka":[],"tldr":"A phase 3 trial of Osimertinib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","summary":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) is a phase 3 interventional study registered as NCT05629234 by AstraZeneca, with 37 participants enrolled, started 2023-05-08 and due to reach its primary completion in 2027-02-22. Interventions recorded: Osimertinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05629234","url":"https://clinicaltrials.gov/study/NCT05629234"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["osimertinib"],"companies":["astrazeneca","parexel"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05629234","phase":"3","setting":"ROSY-T: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment","sponsor":"AstraZeneca","enrolled":37,"outcomes":[]},"route":"/trials/nct05629234/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"parexel","kind":"company","name":"Parexel","route":"/companies/parexel/"}]}}